Miller on Oncology

Kathy D. Miller, MD, is associate director of clinical research at the Melvin and Bren Simon Cancer Center at Indiana University. Her research combines laboratory and clinical research in breast cancer. She is chair of the ECOG-ACRIN Breast Core Committee, where she works with academic scientists and community oncologists to develop trials that combine clinical and biologic endpoints yet remain feasible in nonacademic settings. In addition, she serves as principal investigator of the National Clinical Trials Network at Indiana University.

+ Add to Email Alerts

What Explains 'Sobering' Variations in Breast Cancer Care? Kathy Miller discusses results from a recent study illustrating the impact of geography on breast cancer care.
Medscape Oncology, April 28, 2022
Managing a Loved One's Finances: 'Do You Have a Magic Book?' Kathy Miller discusses the importance of preparing financial information for loved ones to access in the case of medical emergencies.
Medscape Oncology, April 25, 2022
ASCO 2021 Real-World Breast Cancer Tx Fall Far Short of Trial Outcomes Dr Kathy Miller discusses a recent report highlighting the difference in outcomes among clinical trials and real-world settings.
Medscape Oncology, November 11, 2021
Adjuvant IO Fails in BRCA+ Breast Cancer Patient; Now What? Dr Kathy Miller discusses potential treatment options for patients with triple-negative breast cancer.
Medscape Oncology, October 01, 2021
We Need to Level With Our Patients About Tumor Sequencing A recent look at the real-world benefits of tumor sequencing suggests that it may be a mixed bag for patients, says Dr Kathy Miller.
Medscape Oncology, August 27, 2021
Looking for a Good Read? Two End-of-Summer Book Recommendations Dr Kathy Miller provides two end-of-summer science book club recommendations.
Medscape Oncology, August 26, 2021
ASCO 2021 For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.
Medscape Oncology, June 15, 2021
ASCO 2021 Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer Dr Kathy Miller shares the 'biggest news in the breast cancer world' from ASCO, with presented data showing the benefit of olaparib in patients with high-risk, BRCA-mutated HER2-negative disease.
Medscape Oncology, June 11, 2021
ASCO 2021 ASCO 2021: Breast Cancer Sessions Not to Miss Dr Kathy Miller discusses anticipated highlights of ASCO 2021.
Medscape Oncology, June 02, 2021
The Power of Independent Data Monitoring Committees Is Diminishing Dr Kathy Miller sees the power of IDMCs eroding, and warns that this will lead to a loss of confidence in the safety and reliability of new treatments.
Medscape Oncology, May 05, 2021
Single-Cell Sequencing Upends Breast Cancer Assumptions This study turns previous assumptions about the genesis of breast cancers on its head, says Dr Kathy Miller.
Medscape Oncology, April 28, 2021
Margetuximab for HER2+ Metastatic Breast Cancer Falls Short With such a small improvement in progression-free survival, margetuximab is 'simply not enough' for advanced HER2+ breast cancer, says Dr Kathy Miller.
Medscape Oncology, January 07, 2021
CONTESSA: Oral Taxane Meets Primary Endpoint FDA is likely to approve this formulation, says Dr Kathy Miller.
Medscape Oncology, January 06, 2021
RxPONDER: Chemo 'No Longer a Mandate' for Some With Breast Cancer Dr Kathy Miller shares the impactful results of the RxPONDER trial presented at the San Antonio Breast Cancer Symposium.
Medscape Oncology, January 04, 2021
ESMO 2020 Opposing Trial Results on CDK Inhibitors Means Good Science The results of monarchE and PALLAS are creating more questions than answers. Dr Kathy Miller explains why that is a good thing.
Medscape Oncology, October 07, 2020
ESMO 2020 Innate Immune Response Produces 'Phenomenal' Breast Cancer Control A unique study illustrates the extraordinary power of the immune system to control cancer when it's able to recognize the tumor.
Medscape Oncology, October 01, 2020
ESMO 2020 For Immunotherapy in TNBC, Nab-paclitaxel Is a Must Why are results so different between IMpassion130 and IMpassion131? There is no clear answer, says Dr Kathy Miller.
Medscape Oncology, September 24, 2020
Surprising Results From the PALLAS Trial Dr Kathy Miller discusses the surprising -- and disappointing -- results from the PALLAS trial, which caught many off-guard by being announced via press release after the virtual ASCO meeting.
Medscape Oncology, July 01, 2020
In Breast Cancer, Is Chemobrain Really 'Endocrine Brain'? Dr Kathy Miller explores how new data from the TAILORx trial change our understanding of a common but -- to date -- poorly defined side effect.
Medscape Oncology, June 22, 2020
Three Practice-Informing Breast Cancer Trials From ASCO 2020 Dr Kathy Miller comments on three breast cancer trials presented at this year's virtual ASCO meeting and notes that even a negative trial can have a silver lining.
Medscape Oncology, June 18, 2020
ASCO Plenary Highlights Importance of Publicly Funded Research The question posited by the E2108 study, which is being presented at this year's ASCO annual meeting, may not have a financial incentive, but it is vital for clinical practice.
Medscape Oncology, May 29, 2020
Let's Not 'Waste' COVID-19: Opportunities for Improvement Dr Kathy Miller discusses beneficial changes that have resulted from the COVID-19 pandemic and implications for the future of medicine.
Medscape Oncology, May 07, 2020
De-escalation of Cancer Treatment: When Is Less Really More? 'We've gotten very comfortable overtreating people,' says Dr Kathy Miller. Listen in as she and Dr Eric Winer discuss the controversial concept of de-escalating therapy for breast cancer.
Medscape Oncology, February 05, 2020
As Home Genetic Tests Flood Market, Are Physicians Being Left Behind? Direct-to-consumer genetic testing has made it more accessible to patients. Drs Kathy Miller and Susan Domchek discuss the implications involved with this testing for patients and physicians.
Medscape Oncology, January 22, 2020
Three Questions Can Help Quantify Health Disparities Drs Kathy Miller and Samilia Obeng-Gyasi discuss research on whether health disparities affect outcomes in clinical trials, and how collecting certain patient information upfront can make a difference.
Medscape Oncology, January 14, 2020
Early ImmunoRx Results in TNBC 'Put Us in a Difficult Position' Major differences in the results of two separate studies with addition of immunotherapy in triple-negative breast cancer are making this space more complicated than clear, according to Dr Kathy Miller.
Medscape Oncology, January 14, 2020
'Huge Year' for HER2+ Breast Cancer: Incorporating New Treatments Drs Kathy Miller and Sara Hurvitz reflect on some of the trial results, including HER2CLIMB and DESTINY-Breast01, presented at this year's SABCS that may 'take your breath away.'
Medscape Oncology, December 27, 2019
Remembering Bernie: An Early Champion in Breast Cancer Dr Kathy Miller remembers Dr Bernard Fisher and his substantial contributions to the field of breast cancer.
Medscape Oncology, November 01, 2019
Is the 'Value' Movement Affecting Everyday Oncology Practice? 'It's finally starting to happen.' Drs Miller, Saltz, and Schwartzberg discuss how the concept of value is both changing and challenging the cancer care community.
Medscape Oncology, July 18, 2019
Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals Drs Miller and Burstein discuss advances presented at ASCO 2019 in immunotherapy, CDK4/6 inhibitors, and neoadjuvant TDM-1 therapies for breast cancer.
Medscape Oncology, June 07, 2019
'Pendulum Has Swung Too Far' in Opioid Limits for Cancer Pain Dr Kathy Miller discusses the impact of the opioid epidemic on patients with metastatic disease.
Medscape Oncology, April 25, 2019
Breast Cancer Genetic Testing Guidelines 'Simply Are Not Effective' Kathy Miller discusses current breast cancer genetic testing guidelines and considerations for more widespread genetic testing.
Medscape Oncology, April 18, 2019
Let's Put Breast Implant Lymphoma Risk in Context Dr Kathy Miller discusses the importance of placing risks in context, and questions the level of side-effect risk required for fully informed consent.
Medscape Oncology, April 09, 2019
Randomized Data (Finally) on Partial Breast Irradiation Drs Julia White and Kathy Miller discuss the informative and long-awaited results of the NSABP B-39/RTOG 0413 trial comparing whole vs partial breast irradiation.
Medscape Oncology, February 05, 2019
#MeToo Era Presents Complex Questions for Oncology Drs Kathy Miller and Reshma Jagsi discuss research findings and important issues related to sexual harassment and discrimination.
Medscape Oncology, January 29, 2019
Hudis on CancerLinQ: Goal Is Real-Time 'Accident Avoidance System' CancerLinQ is a 'huge, expensive, cumbersome, and complex project, but it's also fun and rewarding to make it happen.' Kathy Miller talks with ASCO CEO Cliff Hudis about this challenging project.
Medscape Oncology, January 22, 2019
Interpreting the 'Messy Early Days' of Immunotherapy in Breast Cancer Peter Schmid, the 'Most Popular Man in San Antonio,' discusses the long-awaited results of IMpassion130, the ground-breaking trial evaluating immunotherapy for metastatic triple-negative breast cancer.
Medscape Oncology, December 13, 2018
Kathy Miller on IMpassion130: New Standard? Not Yet New standard of care? Not so fast, says Kathy Miller.
Medscape Oncology, November 08, 2018
'No Excuse' for Undisclosed COI, but Perhaps a Simple Solution Kathy Miller offers a simple solution to a complex problem.
Medscape Oncology, October 09, 2018
Diagnosing Inflammatory Breast Cancer: Can We Get on the Same Page? 'I know it when I see it' is just not good enough, says Dr Kathy Miller.
Medscape Oncology, September 18, 2018
Are Oncology Pathways 'Achieving the Goals We Promised'? Dr Kathy Miller talks with Dr Robin Zon about ASCO's effort to assess clinical pathways programs, and whether pathways programs are transparent and evidence-based in their recommendations.
Medscape Oncology, July 05, 2018
Clinical Pathways: Many Potential Benefits but 'More Work to Do' Drs Miller and Zon discuss the current challenges associated with clinical pathways in oncology.
Medscape Oncology, June 20, 2018
TAILORx Provides 'Clear Answer' for ER+ Breast Cancer Lead investigator Joseph Sparano discusses the pivotal TAILORx trial presented at ASCO 2018. It's a 'great day for patients,' says Kathy Miller.
Medscape Oncology, June 13, 2018
Long-Awaited TAILORx Results 'Will Impact Your Practice' 'Do not miss' the results of TAILORx this year at ASCO 2018, says Dr Kathy Miller, because they will likely affect management of ER-positive breast cancer.
Medscape Oncology, May 30, 2018
'False Hope' Over Immunotherapy? The Media's Misguided Effects Dr Kathy Miller responds to a recent New York Times article documenting rare immunotherapy responses, which may lead to false hope among cancer patients and their families.
Medscape Oncology, March 05, 2018
'Cultural Change' in DCIS Some think it's time to change how we talk about DCIS and to consider de-escalation of therapy. Drs Kathy Miller and Shelley Hwang discuss these hot topics and the COMET study at SABCS 2017.
Medscape Oncology, January 17, 2018
Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.
Medscape Oncology, January 17, 2018
Will Immunotherapy Be a PANACEA for Breast Cancer? Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC.
Medscape Oncology, January 02, 2018
For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.
Medscape Oncology, December 29, 2017
Does Breast Cancer Risk REACT to Celecoxib? Does this COX-2 inhibitor alter breast cancer risk? Dr Kathy Miller discusses the results of the REACT trial with its primary investigator, Dr Charles Coombes.
Medscape Oncology, December 27, 2017
Hot Topics (and Hot Chilis): SABCS 2017 Dr Kathy Miller highlights potential practice-changing studies that she is looking forward to at SABCS 2017.
Medscape Oncology, December 05, 2017
Two 'P' Words Top List of Hot Topics in Breast Cancer Dr Kathy Miller points to PARP inhibitors and pertuzumab as highpoints of the breast cancer program at the upcoming ASCO meeting, including the plenary presentation of the OlympiAD trial.
Medscape Oncology, May 26, 2017
Should High-Risk Breast Cancer Patients Go Back on an AI? Drs Kathy Miller and Hyman Muss discuss implications of the MA-17R study on long-term AI therapy in breast cancer patients and what the study tells us about management of patients 65 or older.
Medscape Oncology, September 09, 2016
Vitamin D: A New Intervention for Melanoma? Does the association of low vitamin D levels and poor outcomes in melanoma patients point to supplementation as a potential intervention for melanoma?
Medscape Oncology, July 29, 2016
Will Real-World 'Bias' of Big Data Improve Cancer Care? Drs Kathy Miller and Peter Yu discuss how big data can complement the evidence derived from clinical trials, and why the 'bias' of big data is a valuable reflection of real-world practice.
Medscape Oncology, July 08, 2016
Trastuzumab Biosimilar: An Understudy Waits in the Wings Drs Miller and Rugo talk about the trastuzumab biosimilar and what it could mean for patient care worldwide, the lessons from a failed vaccine study, and a practice change that can prevent stomatitis.
Medscape Oncology, June 22, 2016
Can Guidelines Spur Political Action in MBC? Drs Cardoso and Miller discuss consensus guidelines that could improve care and median survival of metastatic breast cancer patients, if more clinicians worldwide were aware of them.
Medscape Oncology, June 17, 2016
Breast Cancer: Big Questions Answered? Dr Kathy Miller previews the top ASCO 2016 breast cancer studies, which may provide definitive answers about anthracyclines in HER2-negative BC and optimal duration for adjuvant aromatase inhibitors.
Medscape Oncology, May 24, 2016
Bread Comas and Other Not-to-Miss Chicago Treats Dr Kathy Miller shares her favorite Chicago pizzerias (the ones the locals want to keep secret) and other Chicago treats to enjoy during ASCO. Why not share your own Chicago guilty pleasures?
Medscape Oncology, May 23, 2016
On Mother's Day, Let's Think About Our Patients Dr Kathy Miller takes a moment to consider how cancer affects families, especially the children of cancer patients, and urges you to give a special hug to your patients who are mothers.
Medscape Oncology, May 05, 2016
Big Data vs Breast Cancer Trials Raises Big Issues Using big data in place of clinical trials to answer clinical questions may sound progressive. But judging from the results of a recent study, it raises big issues, says Dr Kathy Miller.
Medscape Oncology, April 27, 2016
Ovarian Suppression in BC: Right or Wrong, Depending Dr Kathy Miller asks ASCO guidelines author Dr Harold Burstein which early breast cancer patients should -- and should not -- receive ovarian suppression, and how best to manage its side effects.
Medscape Oncology, March 18, 2016
Benefits of Additional Chemo in Residual Breast Cancer Drs Kathy Miller and Bryan Schneider discuss the surprising CREATE-X findings, which show improved survival using more chemotherapy in triple-negative breast cancer patients with residual disease.
Medscape Oncology, February 29, 2016
Out-of-Pocket Can Mean Cancer Meds Are Out Drs Kathy Miller and Dawn Hershman discuss factors in adherence to cancer medications, including cost and side effects, and what clinicians can do to keep patients on their medications.
Medscape Oncology, February 22, 2016
Not to Diss Denosumab, but More Data Needed in Breast Cancer Is it time to jump on the bisphosphonate bandwagon? Drs Kathy Miller and George Sledge review the adjuvant use in breast cancer and discuss new data on denosumab to make sense of all the controversy.
Medscape Oncology, February 22, 2016
From Bedside to Bench: A New Direction in Breast Cancer Research Past AACR president Dr Carlos Arteaga describes translational studies and emerging therapies that are transforming the clinical practice of breast cancer.
Medscape Oncology, January 12, 2016
Breast Cancer and Pregnancy: POSITIVE Study Welcome Dr Kathy Miller discusses a study of outcomes among children born to women with cancer, and an ongoing study of stopping antiestrogen therapy for women with breast cancer who want to become pregnant.
Medscape Oncology, December 28, 2015
Pembrolizumab Shows Durable Responses in TNBC Single-agent PD-L1 antibodies in triple-negative breast cancer show exceptionally durable responses, raising hope for stronger responses with combination therapies, says Dr Hope Rugo from SABCS 2015.
Medscape Oncology, December 21, 2015
Jury Still Out on Anthracyclines in HER2+ Breast Cancer Dr Sara Tolaney highlights studies in HER2-positive breast cancer from SABCS 2015, including the less-than-definitive 10-year results of the BCIRG 006 study.
Medscape Oncology, December 15, 2015
SABCS Promises 'Seismic Tremors' for Breast Cancer Dr Kathy Miller previews several provocative and likely practice-changing studies to be presented at 2015 SABCS.
Medscape Oncology, December 07, 2015
Oncologist Asks for Your Second Opinion Dr Kathy Miller asks what you would do in a second-opinion workup to determine whether a breast cancer patient needs a change in management, and to compare it with the workup she actually received.
Medscape Oncology, July 20, 2015
Money Talks: Solution to Soaring Costs of Cancer Drugs? A panel of oncologists and patient advocates takes on the challenge of what to do about rising cancer care costs--and hits upon a solution both simple and challenging: talk to patients about money.
Medscape Oncology, June 15, 2015
SHAVE a Big Plus in Breast Cancer Dr Kathy Miller makes her top picks of breast cancer studies to watch at ASCO, noting trials in ER-positive and HER2-positive disease--and a small surgical study that may yield big benefits.
Medscape Oncology, May 22, 2015
Is Patient’s 'Right to Try' Law All Wrong? Indiana's new 'right to try' law, which allows terminally ill patients access to experimental drugs for compassionate use, offers nothing, but potential harm, says Dr Kathy Miller.
Medscape Oncology, April 06, 2015
Pertuzumab and the Curious Case of Accelerated Registration Drs Kathy Miller, Clifford Hudis, and George Sledge discuss the pros and cons of testing novel breast cancer treatments in the neoadjuvant setting, with special reference to pertuzumab.
Medscape Oncology, February 09, 2015
Sorting Therapy Options in Locoregional Breast Cancer Drs Richard Zellar and Kathy Miller, at SABCS 2014, discuss locoregional breast cancer therapies, including partial breast irradiation, surgery vs radiation of sentinel nodes, and DCIS scoring.
Medscape Oncology, February 05, 2015
Weight Loss WINS in Breast Cancer Women overweight when diagnosed with breast cancer have poorer outcomes. Drs Kathy Miller and Jennifer Ligibel discuss how to motivate patients to alter their lifestyles to lower their risk.
Medscape Oncology, December 24, 2014
SABCS Wrap-up: Will TNT Quietly Change Practice? Drs Kathy Miller and George Sledge review the surprises and intrigues of SABCS, from its start in 1977 to the best scientific and practice-changing studies presented in 2014.
Medscape Oncology, December 22, 2014
HER2+ Therapy: Getting Less Toxic All the Time Drs Kathy Miller and Clifford Hudis discuss at SABCS 2014 recent advances in HER2+ breast cancer, focusing on the growing interest in lowering the toxicity of therapy.
Medscape Oncology, December 22, 2014
SOFT Yields Hard Data on Hormone Therapy Drs Kathy Miller and Ann Partridge drill down on the practice-changing data from the SOFT trial, indicating which breast cancer patients should receive ovarian suppression.
Medscape Oncology, December 22, 2014
TNT Refines Platinum Use in TNBC Drs Kathy Miller and Andrew Tutt discuss the findings of the important TNT trial, which indicates the significance of knowing BRCA status in using platinums for triple-negative breast cancer.
Medscape Oncology, December 22, 2014
SOFT Trial Landing at SABCS Dr Kathy Miller's preview of SABCS 2014 spotlights key data in triple-negative, HER2+, and local-regional disease as well as the much-anticipated results from the SOFT trial.
Medscape Oncology, December 01, 2014
BRCA Screening: Good Sense or Gattaca Rising? Does population screening for BRCA mutations portend a eugenics future, as in 'Gattaca,' or a practical means to reduce the risk for breast and ovarian cancer? Dr. Kathy Miller weighs the issues.
Medscape Oncology, September 24, 2014
Will Clinical Pathways Go the Way of the Dinosaur? Dr. Kathy Miller contrasts standardization of therapy, as demonstrated by pathways, with the trend of individualizing care on the basis of genomics, and asks: Will pathways will lead to extinction?
Medscape Oncology, September 15, 2014
'Got It Right': Guidelines for HER2-Negative Breast Cancer Dr. Kathy Miller says the ASCO guidelines for advanced HER2-negative breast cancer 'got it right,' focusing on HT, sequential chemo agents, and decisions made jointly by doctors and patients.
Medscape Oncology, September 10, 2014
Is Fast MRI Better Than Mammography? Dr. Kathy Miller reports on a study showing 'fast' MRI is faster, cheaper, and more accurate than conventional MRI, and is better than mammography for screening certain women for breast cancer.
Medscape Oncology, August 18, 2014
ASCO President on the Triumph of the Open Mind Dr. James Holland, president of ASCO in 1976-1977, talks to Dr. Kathy Miller about the early days of oncology, the society, and the humanist passion that is a driving force for both.
Medscape Oncology, June 24, 2014
ASCO Presidents Survey 50 Years of Oncology Three ASCO presidents chart the course of the Society -- and oncology as a whole -- over the past 50 years, from a tentative first meeting to a global influence for cancer research and practice.
Medscape Oncology, June 23, 2014
Oncology and ASCO: A Family Affair Drs. Erica Mayer and Robert Mayer, father and daughter oncologists and colleagues, talk about the bond created by their common work.
Medscape Oncology, June 12, 2014
Results Flat in ALTTO Breast Cancer Trial Drs. Kathy Miller and Karen Gelmon reflect on the major breast cancer data presented at ASCO 2014, and how they will influence practice.
Medscape Oncology, June 06, 2014
Breast Cancer Preview: Critical Issues Resolved? Dr. Kathy Miller sees a subspecialty in transition as she previews the breast cancer sessions at ASCO and highlights plenary studies that may resolve questions of critical importance to patients.
Medscape Oncology, May 22, 2014
Prevention: Stop Cancer Before It Starts Dr. Kathy Miller says prevention is the best way to improve cancer mortality and points out that cancer prevention should become the main focus of primary care practice.
Medscape Oncology, April 16, 2014
The Hero Behind Dr. Larry Einhorn Dr. Kathy Miller talks about John Cleland, who at age 23 with metastatic testis cancer enrolled in the first cisplatin-based trial in 1974, knowing that the investigational drug might offer him no benefit.
Medscape Oncology, March 17, 2014
Breast Cancer Immunogenic: Who Knew? Drs. Kathy Miller and Christos Sotiriou have a candid discussion about tumor-infiltrating lymphocytes and their role in the prognosis and future treatment of breast cancer.
Medscape Oncology, December 24, 2013
Finally! Data in Low-Risk HER2 Breast Cancer Drs. Kathy Miller and Ian Krop talk about why a single-arm study in low-risk cancer is a huge advance for a population of understudied breast cancer patients.
Medscape Oncology, December 24, 2013
'Cutting Edge' in Local Breast Cancer Therapy Why has local therapy for breast cancer become more interesting, more complicated, and more important? Drs. Kathy Miller and Michael Dixon discuss the top studies in local therapy from SABCS 2013.
Medscape Oncology, December 23, 2013
HOPE Gets the Breast Cancer Joint Rockin’ Exercise has many benefits for breast cancer survivors, including keeping them on their aromatase inhibitors. Drs. Kathy Miller and Jennifer Ligibel discuss results of the HOPE study from SABCS 2013.
Medscape Oncology, December 23, 2013
Is Platinum the Silver Lining for TNBC? Drs. Kathy Miller and Hope Rugo discuss why platinum is a good option in triple-negative breast cancer, drawing from evidence presented at SABCS 2013.
Medscape Oncology, December 20, 2013
The Whole Enchilada: What's Hot at SABCS 2013 Dr. Kathy Miller previews SABCS 2013, highlighting studies on platinum agents in triple-negative breast cancer, trends in local therapy, and whether CTC levels should guide therapy decisions.
Medscape Oncology, November 27, 2013
Lifestyle Intervention: 5-Year Benefit in Prostate Cancer A 3-month lifestyle intervention showed benefit at 5 years in men with low-risk prostate cancer, underscoring for Dr. Kathy Miller the importance of lifestyle in the lives of cancer patients.
Medscape Oncology, November 07, 2013

No Results